Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 102.38
EXAS's Cash-to-Debt is ranked higher than
67% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.44 vs. EXAS: 102.38 )
Ranked among companies with meaningful Cash-to-Debt only.
EXAS' s Cash-to-Debt Range Over the Past 10 Years
Min: 12.24  Med: No Debt Max: No Debt
Current: 102.38
Equity-to-Asset 0.93
EXAS's Equity-to-Asset is ranked higher than
89% of the 208 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. EXAS: 0.93 )
Ranked among companies with meaningful Equity-to-Asset only.
EXAS' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.41  Med: 0.77 Max: 0.96
Current: 0.93
-0.41
0.96
Debt-to-Equity 0.01
EXAS's Debt-to-Equity is ranked higher than
92% of the 141 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.31 vs. EXAS: 0.01 )
Ranked among companies with meaningful Debt-to-Equity only.
EXAS' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01  Med: 0.01 Max: 0.33
Current: 0.01
0.01
0.33
Piotroski F-Score: 6
Altman Z-Score: 76.93
Beneish M-Score: -0.82
WACC vs ROIC
6.59%
-373.82%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % -84.38
EXAS's Operating Margin % is ranked lower than
75% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.05 vs. EXAS: -84.38 )
Ranked among companies with meaningful Operating Margin % only.
EXAS' s Operating Margin % Range Over the Past 10 Years
Min: -5591.71  Med: -420.54 Max: 1150.29
Current: -84.38
-5591.71
1150.29
Net Margin % -83.08
EXAS's Net Margin % is ranked lower than
75% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.21 vs. EXAS: -83.08 )
Ranked among companies with meaningful Net Margin % only.
EXAS' s Net Margin % Range Over the Past 10 Years
Min: -5564.4  Med: -403.8 Max: 1123.53
Current: -83.08
-5564.4
1123.53
ROE % -39.15
EXAS's ROE % is ranked lower than
71% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.23 vs. EXAS: -39.15 )
Ranked among companies with meaningful ROE % only.
EXAS' s ROE % Range Over the Past 10 Years
Min: -505.37  Med: -50.88 Max: -26.92
Current: -39.15
-505.37
-26.92
ROA % -35.15
EXAS's ROA % is ranked lower than
70% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.45 vs. EXAS: -35.15 )
Ranked among companies with meaningful ROA % only.
EXAS' s ROA % Range Over the Past 10 Years
Min: -95.07  Med: -45.88 Max: -18.9
Current: -35.15
-95.07
-18.9
ROC (Joel Greenblatt) % -339.18
EXAS's ROC (Joel Greenblatt) % is ranked lower than
77% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.76 vs. EXAS: -339.18 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
EXAS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -3463.3  Med: -1718.22 Max: -339.18
Current: -339.18
-3463.3
-339.18
3-Year Revenue Growth Rate 151.60
EXAS's 3-Year Revenue Growth Rate is ranked higher than
99% of the 156 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.50 vs. EXAS: 151.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
EXAS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -12.2 Max: 302.1
Current: 151.6
0
302.1
3-Year EBITDA Growth Rate 31.60
EXAS's 3-Year EBITDA Growth Rate is ranked higher than
83% of the 142 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. EXAS: 31.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
EXAS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -39.4  Med: -11.95 Max: 46.1
Current: 31.6
-39.4
46.1
3-Year EPS without NRI Growth Rate 33.20
EXAS's 3-Year EPS without NRI Growth Rate is ranked higher than
84% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.80 vs. EXAS: 33.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
EXAS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -43.1  Med: -14.35 Max: 46.5
Current: 33.2
-43.1
46.5
GuruFocus has detected 5 Warning Signs with Exact Sciences Corp $EXAS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» EXAS's 30-Y Financials

Financials (Next Earnings Date: 2017-10-26 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

EXAS Guru Trades in Q3 2016

Paul Tudor Jones 32,756 sh (New)
Jim Simons 365,300 sh (New)
Joel Greenblatt 53,252 sh (+201.39%)
Steven Cohen Sold Out
PRIMECAP Management 4,491,300 sh (-0.55%)
Columbia Wanger 558,434 sh (-27.48%)
» More
Q4 2016

EXAS Guru Trades in Q4 2016

Steven Cohen 153,000 sh (New)
Columbia Wanger 864,133 sh (+54.74%)
PRIMECAP Management 4,491,300 sh (unchged)
Joel Greenblatt Sold Out
Jim Simons Sold Out
Paul Tudor Jones Sold Out
» More
Q1 2017

EXAS Guru Trades in Q1 2017

Joel Greenblatt 56,048 sh (New)
Pioneer Investments 62,559 sh (New)
Jim Simons 351,300 sh (New)
Steven Cohen 2,500,476 sh (+1534.30%)
PRIMECAP Management 4,491,300 sh (unchged)
Columbia Wanger 353,799 sh (-59.06%)
» More
Q2 2017

EXAS Guru Trades in Q2 2017

Paul Tudor Jones 28,500 sh (New)
Pioneer Investments 425,242 sh (+579.75%)
Joel Greenblatt 182,085 sh (+224.87%)
Jim Simons 808,600 sh (+130.17%)
PRIMECAP Management 4,501,300 sh (+0.22%)
Columbia Wanger 266,096 sh (-24.79%)
Steven Cohen 455,200 sh (-81.80%)
» More
» Details

Insider Trades

Latest Guru Trades with EXAS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2017-06-30 Add 224.87%0.06%$22.47 - $38.31 $ 45.8049%182,085
Joel Greenblatt 2017-03-31 New Buy0.02%$13.41 - $23.62 $ 45.80131%56,048
Joel Greenblatt 2016-12-31 Sold Out 0.01%$13.36 - $20.15 $ 45.80184%0
Joel Greenblatt 2016-09-30 Add 201.39%0.01%$11.86 - $21.49 $ 45.80160%53,252
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 621511    SIC: 8731
Compare:NAS:INCR, NYSE:CRL, NAS:DXCM, NAS:PRAH, NAS:BRKR, NAS:PRXL, NYSE:ALR, NAS:VWR, NYSE:BIO, NYSE:PKI, NAS:NEOG, NAS:MYGN, NAS:QDEL, NAS:FMI, NAS:AXDX, NAS:VREX, NAS:MEDP, NAS:GHDX, NAS:BEAT, NAS:ABAX » details
Traded in other countries:EXK.Germany,
Headquarter Location:USA
Exact Sciences Corp operates in the healthcare sector. It is a diagnostics company focused on the early detection and prevention of colorectal cancer.

Exact Sciences is a molecular diagnostics company focused on the early detection and prevention of certain types of cancer. Its core product is a noninvasive screening test, Cologuard, which analyzes stool-based DNA samples to detect the precancerous and early stages of colorectal cancer. The test includes DNA markers and a protein marker that can detect blood in the stool. Exact Sciences receives revenue from two sources: laboratory services and licensing fees. Its laboratory services revenue is generated by diagnostic services that use the Cologuard test. Exact Sciences also receives revenue from the licensing of its product rights.

Guru Investment Theses on Exact Sciences Corp

Meridian Funds Comments on Exact Sciences Corp - May 18, 2017

Exact Sciences Corp. (NASDAQ:EXAS) develops noninvasive molecular screening tests for the early detection and prevention of colorectal cancer. We originally invested in the company because Cologuard, its revolutionary product, exhibited low market penetration and significant opportunity for continued adoption. Test accuracy versus other non-invasive tests has led to improved adoption rates and recent annual revenue growth in excess of 150%. Large commercial insurer, Aetna, recently announced its decision to cover the screening for qualified members. In this positive environment, Exact Sciences raised its test volume expectations to 415,000 for the year and noted meaningful gross margin improvement as its business model continues to scale faster than expected. As such, we are maintaining our position.



From Meridian Growth Funds first-quarter 2017 shareholder commentary.



Check out Meridian Funds latest stock trades

Top Ranked Articles about Exact Sciences Corp

Exact Sciences to participate in Baird Global Healthcare Conference
Exact Sciences to participate in Canaccord Genuity Growth Conference
Cologuard® revenue increased to $57.6 million during second quarter; Test volume grew 149 percent from second quarter of 2016 to 135,000 completed tests
Exact Sciences Grants Inducement Restricted Stock Unit Awards to Recently Hired Employees
Exact Sciences to host second-quarter 2017 results, annual meeting webcasts and calls
Jerry Kelly and Exact Sciences Team Up to Promote Colon Cancer Screening
Exact Sciences Announces Pricing of Public Offering of Common Stock
Exact Sciences Announces Agreement to Sell 7,000,000 Common Shares
Exact Sciences to participate in June investor conferences
Meridian Funds Comments on Exact Sciences Corp Guru stock highlight
Exact Sciences Corp. (NASDAQ:EXAS) develops noninvasive molecular screening tests for the early detection and prevention of colorectal cancer. We originally invested in the company because Cologuard, its revolutionary product, exhibited low market penetration and significant opportunity for continued adoption. Test accuracy versus other non-invasive tests has led to improved adoption rates and recent annual revenue growth in excess of 150%. Large commercial insurer, Aetna, recently announced its decision to cover the screening for qualified members. In this positive environment, Exact Sciences raised its test volume expectations to 415,000 for the year and noted meaningful gross margin improvement as its business model continues to scale faster than expected. As such, we are maintaining our position. Read more...

Ratios

vs
industry
vs
history
PB Ratio 9.63
EXAS's PB Ratio is ranked lower than
92% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.89 vs. EXAS: 9.63 )
Ranked among companies with meaningful PB Ratio only.
EXAS' s PB Ratio Range Over the Past 10 Years
Min: 1.69  Med: 7.13 Max: 36.44
Current: 9.63
1.69
36.44
PS Ratio 30.41
EXAS's PS Ratio is ranked lower than
90% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.65 vs. EXAS: 30.41 )
Ranked among companies with meaningful PS Ratio only.
EXAS' s PS Ratio Range Over the Past 10 Years
Min: 9.83  Med: 46.49 Max: 1325.45
Current: 30.41
9.83
1325.45
EV-to-EBIT -36.47
EXAS's EV-to-EBIT is ranked lower than
99.99% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. EXAS: -36.47 )
Ranked among companies with meaningful EV-to-EBIT only.
EXAS' s EV-to-EBIT Range Over the Past 10 Years
Min: -37.39  Med: -11.6 Max: -0.3
Current: -36.47
-37.39
-0.3
EV-to-EBITDA -40.25
EXAS's EV-to-EBITDA is ranked lower than
99.99% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.58 vs. EXAS: -40.25 )
Ranked among companies with meaningful EV-to-EBITDA only.
EXAS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -41.28  Med: -12.1 Max: -0.4
Current: -40.25
-41.28
-0.4
EV-to-Revenue 30.08
EXAS's EV-to-Revenue is ranked lower than
89% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.97 vs. EXAS: 30.08 )
Ranked among companies with meaningful EV-to-Revenue only.
EXAS' s EV-to-Revenue Range Over the Past 10 Years
Min: 4.3  Med: 38 Max: 1390.2
Current: 30.08
4.3
1390.2
Current Ratio 16.81
EXAS's Current Ratio is ranked higher than
92% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.73 vs. EXAS: 16.81 )
Ranked among companies with meaningful Current Ratio only.
EXAS' s Current Ratio Range Over the Past 10 Years
Min: 1.02  Med: 9.08 Max: 50.84
Current: 16.81
1.02
50.84
Quick Ratio 16.42
EXAS's Quick Ratio is ranked higher than
92% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.17 vs. EXAS: 16.42 )
Ranked among companies with meaningful Quick Ratio only.
EXAS' s Quick Ratio Range Over the Past 10 Years
Min: 1.02  Med: 9.08 Max: 50.84
Current: 16.42
1.02
50.84
Days Inventory 51.66
EXAS's Days Inventory is ranked higher than
59% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 80.72 vs. EXAS: 51.66 )
Ranked among companies with meaningful Days Inventory only.
EXAS' s Days Inventory Range Over the Past 10 Years
Min: 51.66  Med: 79.66 Max: 169.5
Current: 51.66
51.66
169.5
Days Sales Outstanding 48.69
EXAS's Days Sales Outstanding is ranked higher than
74% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.84 vs. EXAS: 48.69 )
Ranked among companies with meaningful Days Sales Outstanding only.
EXAS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 31.32  Med: 45.66 Max: 279.33
Current: 48.69
31.32
279.33
Days Payable 13.38
EXAS's Days Payable is ranked lower than
96% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 57.91 vs. EXAS: 13.38 )
Ranked among companies with meaningful Days Payable only.
EXAS' s Days Payable Range Over the Past 10 Years
Min: 5.73  Med: 1526.07 Max: 249295
Current: 13.38
5.73
249295

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -15.80
EXAS's 3-Year Average Share Buyback Ratio is ranked lower than
70% of the 146 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.50 vs. EXAS: -15.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
EXAS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -217.1  Med: -13.35 Max: -1
Current: -15.8
-217.1
-1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 11.51
EXAS's Price-to-Net-Cash is ranked lower than
59% of the 82 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 12.16 vs. EXAS: 11.51 )
Ranked among companies with meaningful Price-to-Net-Cash only.
EXAS' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.02  Med: 6.63 Max: 90
Current: 11.51
2.02
90
Price-to-Net-Current-Asset-Value 10.53
EXAS's Price-to-Net-Current-Asset-Value is ranked lower than
64% of the 140 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.24 vs. EXAS: 10.53 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
EXAS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.98  Med: 6.46 Max: 60
Current: 10.53
1.98
60
Price-to-Tangible-Book 9.42
EXAS's Price-to-Tangible-Book is ranked lower than
80% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.17 vs. EXAS: 9.42 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
EXAS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.87  Med: 6.07 Max: 33.71
Current: 9.42
1.87
33.71
Price-to-Median-PS-Value 0.64
EXAS's Price-to-Median-PS-Value is ranked higher than
81% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.04 vs. EXAS: 0.64 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
EXAS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.24  Med: 1.34 Max: 185.2
Current: 0.64
0.24
185.2
Earnings Yield (Greenblatt) % -2.74
EXAS's Earnings Yield (Greenblatt) % is ranked lower than
59% of the 230 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.04 vs. EXAS: -2.74 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
EXAS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -300.9  Med: -8.6 Max: -2.68
Current: -2.74
-300.9
-2.68

More Statistics

Revenue (TTM) (Mil) $169.37
EPS (TTM) $ -1.28
Beta0.72
Short Percentage of Float16.90%
52-Week Range $13.05 - 45.80
Shares Outstanding (Mil)119.10

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 240 377 552 765
EPS ($) -1.18 -0.84 -0.05 0.89
EPS without NRI ($) -1.18 -0.84 -0.05 0.89
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}